Welcome to our dedicated page for Petmed Express SEC filings (Ticker: PETS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PetMed Express Inc’s business lives at the intersection of e-commerce and pet healthcare, so its SEC disclosures hold clues that go far beyond routine numbers. Curious about how prescription refills stack up against over-the-counter sales or how marketing spend drives new pet-parent acquisitions? This is where you’ll find out.
Stock Titan’s AI engine turns each dense document into plain-English takeaways. Need the PetMed Express quarterly earnings report 10-Q filing distilled to the metrics that matter—gross margin shifts, customer reorder rates, seasonal flea & tick demand? Our platform surfaces them instantly. Wondering whether executives are buying shares before high-growth quarters? PetMed Express Form 4 insider transactions real-time alerts put that data at your fingertips.
Here’s what you can explore today:
- 10-K insights: inventory turnover, prescription vs OTC mix, and customer acquisition cost—PetMed Express annual report 10-K simplified
- Real-time PetMed Express insider trading Form 4 transactions plus historical trend charts
- PetMed Express proxy statement executive compensation that connects pay to reorder growth
- PetMed Express 8-K material events explained—supplier changes, data-security updates, partnership launches
Every filing type—10-Q, 10-K, 8-K, DEF 14A, and S-8—arrives seconds after EDGAR posts. AI-powered summaries, keyword search, and side-by-side comparisons make understanding PetMed Express SEC documents with AI straightforward. Use our PetMed Express earnings report filing analysis to track margin trends, or monitor PetMed Express executive stock transactions Form 4 before making allocation decisions. Complex pet-pharma disclosures, simplified and updated in real time—so you can focus on actionable insights, not page counts.
PetMed Express, Inc. (PETS) reported that it entered into an amendment to its shareholder rights agreement, extending the final expiration date of the rights until the close of business on December 2, 2026. This keeps its preferred stock purchase rights plan in place for an additional year.
The Board also approved an increase in the annual base salary of Interim Principal Financial Officer and Chief Accounting Officer Douglas Krulik from $300,000 to $330,000, effective as of August 30, 2025. In addition, the Company entered into a Change of Control and General Severance Agreement with Mr. Krulik, providing six months of base-salary severance if he is terminated without cause, and, if such termination or a resignation for good reason occurs within 12 months after a change of control, the same severance plus immediate vesting of his restricted equity awards.
PetMed Express reported receiving a Nasdaq notice on November 12, 2025 for failing to timely file its Quarterly Reports on Form 10‑Q for the periods ended June 30, 2025 (Q1) and September 30, 2025 (Q2), in addition to a prior delinquent Form 10‑K for the year ended March 31, 2025. The notice requires an updated compliance plan by November 28, 2025, and states any staff exception, if granted, will be limited to a maximum of 180 days from the initial delinquency, or December 29, 2025.
The company said the notice has no immediate effect on its Nasdaq listing and it intends to complete and file the Q1 10‑Q and Q2 10‑Q as promptly as possible. Separately, PetMed furnished a press release announcing preliminary, unaudited estimated revenues for the three‑ and nine‑month periods ended September 30, 2025; that information was furnished, not filed, under Item 2.02.
PetMed Express (PETS) filed a Form 12b-25, notifying a late filing of its Form 10-Q for the quarter ended September 30, 2025, as it first needs to complete the delayed June 30, 2025 Form 10-Q following a now-completed Audit Committee investigation.
For the September quarter, net sales are estimated at $43.4–$44.5 million, compared with $58.0 million in the prior-year period. For the six months ended September 30, 2025, net sales are expected at $94.5–$95.6 million, versus $124.3 million a year earlier. The company is analyzing the timing and amount of an anticipated goodwill impairment and cannot currently estimate operating or net income for these periods.
PetMed Express (PETS) reported that its CAO and Interim CFO acquired 20,000 shares of restricted stock on October 30, 2025 at $0, as disclosed on a Form 4.
The award vests as to 50% of the granted shares on October 30, 2026 and 50% on October 30, 2027, subject to continued employment through each vesting date. Following this grant, the officer beneficially owns 70,000 shares.
PetMed Express (PETS) reported a director’s acquisition of 34,866 shares of restricted common stock on 10/30/2025 at $0, as disclosed in a Form 4. Following the award, the director beneficially owns 34,866 shares, held directly. The grant was made under the company’s 2024 Omnibus Incentive Plan and is scheduled to vest in two tranches: 1,020 shares on 10/19/2026 and 33,846 shares on 10/30/2026, each vesting subject to continued service on the Board of Directors.
PetMed Express (PETS) reported a director equity grant. The reporting person acquired 33,846 shares of common stock as a restricted stock award at $0 on October 30, 2025, issued under the company’s 2024 Omnibus Incentive Plan. The award vests as to all granted shares on October 30, 2026, subject to continued service on the Board of Directors. After this transaction, the reporting person beneficially owned 42,719 shares, held directly.
PetMed Express (PETS) director Leah A. Solivan reported an award of 33,846 shares of common stock on 10/30/2025 at $0 (Form 4, code A), granted as restricted stock under the company’s 2024 Omnibus Incentive Plan.
The award vests on October 30, 2026, subject to continued service on the Board of Directors. Following this grant, Solivan’s beneficial ownership is 42,289 shares, held directly.
PetMed Express (PETS) reported a director equity grant on a Form 4. On 10/30/2025, the director acquired 33,846 shares of common stock as a restricted stock award at a reported price of $0, under the company’s 2024 Omnibus Incentive Plan. Following the grant, the director beneficially owned 36,373 shares, held directly.
The award vests in full on October 30, 2026, subject to continued service on the Board of Directors.
PetMed Express (PETS) reported an initial insider ownership filing. Director James LaCamp filed a Form 3 with an event date of 10/19/2025, stating no securities are beneficially owned.
The filing was made by one reporting person and reflects his status as a director of the company.
PetMed Express (PETS) announced board and leadership updates. The Board appointed James LaCamp as a director effective immediately and named him to the Audit Committee and the Compensation and Human Capital Committee. He will become Audit Committee Chair on October 30, 2025 and is designated an SEC “audit committee financial expert.”
The Board also approved an Interim Executive Employment Agreement with Leslie C.G. Campbell to serve as Interim CEO and President for a one-year term from August 11, 2025 through August 10, 2026. The role is at-will and may be terminated by either party without severance. Compensation includes a $1.3 million annual base salary, four weeks of vacation, customary expense reimbursement, and standard employee benefits, with full-time, in-person work at the Delray Beach headquarters. The agreement includes confidentiality, non-solicitation, and a one-year post-employment non-compete. The company furnished the agreement as Exhibit 10.1 and a related press release as Exhibit 99.1.
FAQ
What is the current stock price of Petmed Express (PETS)?
What is the market cap of Petmed Express (PETS)?
